GEN
Gen Digital Inc.Evidence as of 2026-10-13The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on GEN
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · Gen Digital Inc.
Gen Digital Inc. provides cyber safety solutions for consumers in the United States, Canada, Latin America, Europe, the Middle East, Africa, the Asia Pacific, and Japan. It offers security and performance products comprising that provide real-time protection for PCs, Macs and mobile devices against malware, viruses, adware, and other online threats; and Norton and LifeLock identity theft protection solution that offe…
Management team
- Mr. Bryan Seuk Ko J.D. · Chief Legal Officer, Secretary & Head of Corporate DevelopmentFind on LinkedIn
- Ms. Natalie Marie Derse · EVP, CFO & Principal Accounting OfficerFind on LinkedIn
- Mr. Vincent Pilette · CEO, President & DirectorFind on LinkedIn
- Mr. Jason Starr · Head of Investor RelationFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.5 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
What the evidence shows
The evidence balance is cautious ( -0.5 of a possible +2) with high confidence. Revenue rose from $1,220,000,000 in fiscal Q2 2026 (2025-11-04) to $1,240,000,000 in fiscal Q3 2026 (2026-02-03) and to $1,336,000,000 in Q1 2027 (fiscal quarter ended 2026-08-04). Gross profit climbed from $954,000,000 to $972,000,000 to $1,029,000,000 over those quarters while computed gross margins moved from about 78.2% to 78.5% to 77.0%, indicating slight margin compression in the most recent quarter. Operating income remained roughly flat at $438,000,000, $433,000,000 and $443,000,000, while net income and diluted EPS increased to $215,000,000 and $0.36 in Q1 2027; shares outstanding declined to 598,587,032 as of 2026-08-04 with repurchases including $100,000,000 in Q1 2027. Market signals show mixed momentum (6‑month +24.1%, 3‑month -12.1%, 12‑1 +5.0%), elevated volatility (30‑day annualized +55.2%, 90‑day +43.1%), price below the 50‑day SMA by -15.0% and below the 200‑day SMA by -4.2%, and valuation multiples such as P/FCF 10.67, EV/EBITDA 9.44 and P/E ttm 21.23; reported cash versus long‑term debt inputs imply a material net‑debt position.
What the debate changed
No surviving claim was dropped or materially weakened in the debate, so the desk’s original read holds. The analysts argued around interpretation — for example, whether share repurchases and declining long‑term debt materially alter leverage — but those points did not change the surviving evidence or the cautious balance. The added 10‑K risk language about AI, third‑party platform dependence and regulatory exposure remained in place and factored into the risk review.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Revenue (RevenueFromContractWithCustomerExcludingAssessedTax) rose from $1,220,000,000 in fiscal Q2 2026 (2025-07-05 to 2025-10-03) to $1,240,000,000 in fiscal Q3 2026 (2025-10-04 to 2026-01-02) to $1,336,000,000 in fiscal Q1 2027 (2026-04-04 to 2026-07-03).
XBRL companyfacts · 0000849399-25-000092Gross profit (GrossProfit) was $954,000,000 in fiscal Q2 2026, $972,000,000 in fiscal Q3 2026, and $1,029,000,000 in fiscal Q1 2027; gross margin computed from those reported figures is about 78.2% in fiscal Q2 2026 (954/1,220), 78.5% in fiscal Q3 2026 (972/1,240), and 77.0% in fiscal Q1 2027 (1,029/1,336), indicating slight compression of gross margin between the most recent quarter and the prior quarters.
XBRL companyfacts · 0000849399-26-000031Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
The Annual Report on Form 10-K filed 21 May 2026 added a risk saying the company is investing significantly in R&D, including AI, and that if these investments fail or are delayed its operating results could be adversely affected.
Item 1A risk-factor diff · 0000849399-26-000017 vs 0000849399-25-000033The 10-K filed 21 May 2026 added multiple new risk disclosures about the development, integration and deployment of AI (including generative AI), stating AI systems may be flawed, produce incorrect or biased outputs, and that such issues could lead to customer dissatisfaction, reputational harm, litigation, or increased regulatory scrutiny.
Item 1A risk-factor diff · 0000849399-26-000017 vs 0000849399-25-000033Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
Momentum over the last 6 months is +24.1% and ranks in the 83th percentile of the 881-stock research universe as of 2026-10-12.
Moneyta signal set · 2026-10-12weakened in debateShorter-term momentum over the last 3 months is -12.1%, while the 12-1 momentum is +5.0% (44th percentile of 881).
Moneyta signal set · 2026-10-12weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Institutional 13F-reported holdings total $12.99B as of 2026-06-30.
13F holdings · 690 filers · as of 2026-06-30The five largest 13F-reported holders are BlackRock, Inc. $1.33B (value_qoq_pct 33.4), FMR LLC $1.15B (value_qoq_pct 36.8), VANGUARD CAPITAL MANAGEMENT LLC $887.9M (value_qoq_pct 32.5), STATE STREET CORP $777.6M (value_qoq_pct 40.0), and VANGUARD PORTFOLIO MANAGEMENT LLC $757.2M (value_qoq_pct 28.2), per the 2026-06-30 report.
13F holdings · 690 filers · as of 2026-06-30Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Press releases announced Gen executives will participate in upcoming investor conferences, with coverage appearing on finance.yahoo.com on 12 October 2026.
News · finance.yahoo.com · 2026-10-12A PR Newswire release on 12 October 2026 similarly announced Gen's participation in investor conferences, indicating the news was distributed via company press channels and picked up by syndicated outlets.
News · prnewswire.com · 2026-10-12Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Vlcek Ondrej sold 47,462 shares for "$1.4M" on 2026-08-21 (filing shows a sale of 47,462 shares valued at "$1.4M").
Form 4 · Vlcek Ondrej (Director) · $1.4M sold · 2026-08-21Vlcek Ondrej sold 152,358 shares for "$4.4M" on 2026-08-25 (filing shows a sale of 152,358 shares valued at "$4.4M").
Form 4 · Vlcek Ondrej (Director) · $4.4M sold · 2026-08-25Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model-implied free cash flow growth rate that today's price would justify is -5.49%.
Valuation inputs · SEC XBRL + stored EOD closePrice to trailing twelve-month free cash flow is 10.67 (price 23.35 with FCF per share 2.1874 and FCF ttm $1,319,000,000).
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
Several company-specific fundamentals and market-structure items in the record jointly support a favorable read. Reported top-line growth across the three most recent fiscal quarters (fundamentals-0) occurred alongside rising net income and diluted EPS (fundamentals-3), while shares outstanding have meaningfully declined amid active repurchases (fundamentals-4), amplifying per‑share results. Leverage metrics show reported long-term debt trending down across the balance-date snapshots (fundamentals-5), and multiple valuation snapshots indicate the shares trade at single‑digit EV/EBITDA and a mid‑teens PE with a double‑digit price-to‑FCF multiple that implies a meaningful FCF yield (valuation-2, valuation-3, valuation-1). Institutional placement and recent momentum (ownership-0, market-0) add context that investor demand and analyst coverage have not been absent, and recent governance/product items in the press (news-2, news-3) coincide with visible investor interest.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.34
38 surviving claims rest on 17 distinct sources; the heaviest analyst carries 21% of them, and 97% of what the desk raised survived the debate.
The surviving set is moderately broad but not deeply redundant: 38 claims draw on 17 distinct sources, so there is useful cross-evidence, yet a single analyst contribution accounts for a noticeable share and the desk’s high debate-survival rate means few internal challenges reduced claims. Taken together, these fragility signals imply the read is informative but should be weighted with caution—source concentration and limited internal counter-evidence reduce how much confidence to place in any single inference.
Peer context · computed, not argued
12-1 momentum ranks 13th of 23 in Software—Infrastructure (as of 2026-10-12).
6-month relative strength ranks 17th of 23 in Software—Infrastructure (as of 2026-10-12).
90-day volatility ranks 20th of 23 in Software—Infrastructure (as of 2026-10-12).
dividend yield ranks 1st of 21 in Software—Infrastructure (as of 2026-10-12).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
9 filings· 3 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+0.7 to the score
13 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−1.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.1 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.4 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
13 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot−1.0 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on GEN Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.